Main characteristics of patients
Patient no. . | Age (at diagnosis) . | TNM staging* . | Previous treatments† . | PBLs‡ . | Ly§ . | Percent CD4+/CD3+ . | TCRVβ∥(percent CD4+ cells) . | Percent Sézary cells . |
|---|---|---|---|---|---|---|---|---|
| 1 | 79 (69) | T4N3M0 | PUVA, IFNα, ECPC, chlorambucil + prednisone | 11 900 | 4044 | 96.3 | Vβ3 (97.4) | 5 |
| 2 | 78 (71) | T4N1M0 | PUVA, IFNα, ECPC | 8 300 | 2490 | 95.0 | NA | 10 |
| 6 | 72 (64) | T4N3M0 | PUVA | 5 800 | 1600 | 97.2 | Vβ22 (88.2) | 12 |
| 10 | 84 (84) | T4N1M0 | None | 14 100 | 8460 | 94.5 | Vβ5.1 (94.8) | 40 |
| 11 | 67 (62) | T4N3M0 | ECPC | 3 200 | 480 | 48.5 | NA | 8 |
| 18 | 68 (64) | T4N0M0 | PUVA, ECPC + IFNα, CHOP | 11 300 | 6100 | 96.2 | Vβ11 (97.1) | 11 |
| 20 | 66 (66) | T4N3M0 | None | 17 500 | 5780 | 88.0 | Vβ2 (85.1) | 25 |
| 23 | 20 (20) | T4N3M0 | None | 6 500 | 2060 | 86.7 | Vβ5.1 (78.2) | 6 |
| 24 | 59 (59) | T4N3M0 | IFNα | 16 000 | 1760 | 94.9 | Vβ18 (98.7) | 48 |
| 25 | 79 (79) | T4N3M0 | None | 81 300 | 25200 | 98.1 | Vβ13.1 (98.5) | 20 |
| 26 | 63 (59) | T4N3M0 | IFNα, PUVA | 6 700 | 740 | 82.8 | Vβ2 (38.6) | 19 |
| 27 | 76 (76) | T4N3M0 | MTX, mechlorethamine, bexarotene, ECPC + IFNα | 18 900 | 8520 | 99.4 | Vβ213 (83.2) | 39 |
| 28 | 53 (47) | T4N3M0 | IFNα, PUVA, ECPC, CHOP, bexarotene | 17 800 | 6410 | 97.9 | NA | 20 |
| 29 | 55 (55) | T4N3M0 | ECPC, IFNα, mechlorethamine, PUVA, MTX, bexarotene | 9 900 | 1490 | 85.5 | NA | 5 |
| 30 | 65 (65) | T4N1M0 | IFNα, prednisone | 15 200 | 1670 | 87.0 | NA | 6 |
Patient no. . | Age (at diagnosis) . | TNM staging* . | Previous treatments† . | PBLs‡ . | Ly§ . | Percent CD4+/CD3+ . | TCRVβ∥(percent CD4+ cells) . | Percent Sézary cells . |
|---|---|---|---|---|---|---|---|---|
| 1 | 79 (69) | T4N3M0 | PUVA, IFNα, ECPC, chlorambucil + prednisone | 11 900 | 4044 | 96.3 | Vβ3 (97.4) | 5 |
| 2 | 78 (71) | T4N1M0 | PUVA, IFNα, ECPC | 8 300 | 2490 | 95.0 | NA | 10 |
| 6 | 72 (64) | T4N3M0 | PUVA | 5 800 | 1600 | 97.2 | Vβ22 (88.2) | 12 |
| 10 | 84 (84) | T4N1M0 | None | 14 100 | 8460 | 94.5 | Vβ5.1 (94.8) | 40 |
| 11 | 67 (62) | T4N3M0 | ECPC | 3 200 | 480 | 48.5 | NA | 8 |
| 18 | 68 (64) | T4N0M0 | PUVA, ECPC + IFNα, CHOP | 11 300 | 6100 | 96.2 | Vβ11 (97.1) | 11 |
| 20 | 66 (66) | T4N3M0 | None | 17 500 | 5780 | 88.0 | Vβ2 (85.1) | 25 |
| 23 | 20 (20) | T4N3M0 | None | 6 500 | 2060 | 86.7 | Vβ5.1 (78.2) | 6 |
| 24 | 59 (59) | T4N3M0 | IFNα | 16 000 | 1760 | 94.9 | Vβ18 (98.7) | 48 |
| 25 | 79 (79) | T4N3M0 | None | 81 300 | 25200 | 98.1 | Vβ13.1 (98.5) | 20 |
| 26 | 63 (59) | T4N3M0 | IFNα, PUVA | 6 700 | 740 | 82.8 | Vβ2 (38.6) | 19 |
| 27 | 76 (76) | T4N3M0 | MTX, mechlorethamine, bexarotene, ECPC + IFNα | 18 900 | 8520 | 99.4 | Vβ213 (83.2) | 39 |
| 28 | 53 (47) | T4N3M0 | IFNα, PUVA, ECPC, CHOP, bexarotene | 17 800 | 6410 | 97.9 | NA | 20 |
| 29 | 55 (55) | T4N3M0 | ECPC, IFNα, mechlorethamine, PUVA, MTX, bexarotene | 9 900 | 1490 | 85.5 | NA | 5 |
| 30 | 65 (65) | T4N1M0 | IFNα, prednisone | 15 200 | 1670 | 87.0 | NA | 6 |
NA indicates not available.
According to the TNM (tumors-nodes-metastases) classification.
PUVA indicates psoralen with ultraviolet A radiation therapy; IFNα, interferon alpha; MTX, methotrexate; ECPC, extra-corporeal photochemotherapy; CHOP, polychemotherapy regimen containing cyclophosphamide, doxorubicin, vincristine, and prednisone.
PBL indicates peripheral blood leukocytes.
Ly (lymphocytes) expressed as peripheral blood absolute cell counts per cubic millimeter.
The TCRVβ segment expressed by tumoral cells was identified by TCRVβ/CD4 double-immunostaining flow cytometric analysis of PBLs in 10 of the 15 cases described here, as PBLs from patients 2, 11, 28, 29, and 30 did not predominantly immunoreact with any anti-TCVβ monoclonal antibody. Nevertheless, the clonal nature of the expansion was confirmed in all cases by PCR analysis of TCRVγ-Jγ rearranged DNA segments, by Vβ-family—specific RT-PCR, and by immunoscopy analysis of expanded TCRVβ families.